Relay Therapeutics, Inc.
No enriched coverage for $RLAY in the last 7 days.
SVF Pauling (Cayman) Ltd sold 6,000,000 indirectly-held shares of Relay Therapeutics, Inc. (RLAY) at $19.40 ($116.40M total) on 2026-08-25. Filed jointly with SOFTBANK VISION FUND (AIV M2) L.P. (10% owner) and SB INVESTMENT ADVISERS (UK) LTD (10% owner).
Relay Therapeutics (RLAY) reported Q2 results, prompting analysis of its premium P/B multiple. The article highlights 3 key rewards and 2 warning signs for investors to consider. It also suggests diversifying research beyond RLAY and offers strategies for identifying undervalued stocks, reliable dividend payers, and resilient companies.
Patel Sanjiv (President and CEO) sold 48,199 shares of Relay Therapeutics, Inc. (RLAY) at $20.33 ($0.98M total) on 2026-08-17 under a Rule 10b5-1 trading plan.
Recent RLAY coverage spans insider activity, financial news and market movers.
In the last 30 days, RLAY insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($117.8M). The most active reporter was Rahmer Peter, See remarks, with 1 filing. 75% of those filings were made under pre-arranged Rule 10b5-1 plans.
Large insider sell may pressure RLAY price; indicates possible insider concern.
No material news; likely no immediate price impact.
This is a routine insider sale under a 10b5-1 plan, so it is unlikely to signal new fundamental deterioration by itself.
The article frames a momentum-driven rally (new highs, strong technical buy signals) against deteriorating near-term fundamentals (revenue decline).
New primary disclosures include updated cash position, follow-on offering proceeds, and specific clinical development timelines plus initial Phase 1/2 vascular-anomalies response metrics.
alphai scores every news story that mentions RLAY with an AI model for sentiment and relevance, and aggregates insider trades from Relay Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
SVF Pauling (Cayman) Ltd sold 6,000,000 indirectly-held shares of Relay Therapeutics, Inc. (RLAY) at $19.40 ($116.40M total) on 2026-08-25. Filed jointly with SOFTBANK VISION FUND (AIV M2) L.P. (10% owner) and SB INVESTMENT ADVISERS (UK) LTD (10% owner).
1 min readRelay Therapeutics (RLAY) reported Q2 results, prompting analysis of its premium P/B multiple. The article highlights 3 key rewards and 2 warning signs for investors to consider. It also suggests diversifying research beyond RLAY and offers strategies for identifying undervalued stocks, reliable dividend payers, and resilient companies.
2 min readPatel Sanjiv (President and CEO) sold 48,199 shares of Relay Therapeutics, Inc. (RLAY) at $20.33 ($0.98M total) on 2026-08-17 under a Rule 10b5-1 trading plan.
2 min readBarchart reports Relay Therapeutics (RLAY) has risen about 486% over the past 52 weeks and is near a new 3-year high, with Barchart giving a 100% “Buy” opinion and a Trend Seeker “Buy” signal. The article cites $4.4B market cap and expects revenue to fall 31.21% this year before rising next year.
5 min readRelay Therapeutics, Inc. (RLAY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMENDMENT NO. 1 TO THE COMMON STOCK SALES AGREEMENT August 6, 2026 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: This Amendment No. 1 to the Sales Agreement, dated as of August 6, 2026, is entered into by and between Relay
6 min readThe article profiles five biotech/healthcare stocks and cites recent catalysts and upcoming events. Glaukos (GKOS) highlights Epioxa launch and raised 2026 sales guidance ahead of Q2 2026 results July 29, 2026. TG Therapeutics (TGTX) cites BRIUMVI trial updates and Q2 results early August. Corcept (CORT) points to Lifyorli progress and raised guidance. Relay (RLAY) and Nutex Health (NUTX) note Phase 3 and upcoming quarterly results. It lists large post-publication price gains for each.
7 min readPatel Sanjiv (President and CEO) sold 48,199 shares of Relay Therapeutics, Inc. (RLAY) at $19.58 ($0.94M total) on 2026-07-07 under a Rule 10b5-1 trading plan.
2 min readRahmer Peter (See remarks) sold 50,000 shares of Relay Therapeutics, Inc. (RLAY) at $19.09 ($0.95M total) on 2026-06-30 under a Rule 10b5-1 trading plan.
1 min readCatinazzo Thomas (Chief Financial Officer) sold 187,163 shares of Relay Therapeutics, Inc. (RLAY) at an average of $16.97 ($16.97–$17.01, $3.18M total) across 4 trades on 2026-06-22 under a Rule 10b5-1 trading plan.
2 min readBergstrom Donald A (President, R&D) sold 93,456 shares of Relay Therapeutics, Inc. (RLAY) at $16.94 ($1.58M total) on 2026-06-22 under a Rule 10b5-1 trading plan.
2 min read
